Entero Therapeutics, a clinical-stage biopharmaceutical company, has appointed Richard Paolone as the interim CEO. Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions.

The M&A Class Action Firm is investigating the proposed mergers of Summit Materials, Entero Therapeutics, AlloVir, and Staffing 360 Solutions, providing details on the terms of each merger and encouraging shareholders to contact the firm for more information.

Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed mergers and transactions involving Pulmatrix, Liberty Broadband, Entero Therapeutics, and Liberty Media.

Monteverde & Associates PC, a class action law firm, is investigating the proposed merger between Entero Therapeutics, Inc. (ENTO) and Journey Therapeutics, Inc., where Journey Therapeutics shareholders will acquire 99% of Entero's equity.

Entero Therapeutics and Journey Therapeutics announce a proposed reverse merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Journey's next-gen, first-in-class nano-immunoconjugates platform and Entero's gastrointestinal product pipeline.